Lonza, Teva to terminate biosimilars JV

JERUSALEM, ISRAEL/BASEL, SWITZERLAND: Global leader in pharmaceutical ingredients, Lonza Group and Teva Pharmaceutical Industries have decided to discontinue their collaboration (Teva – Lonza joint venture) for the development, manufacturing and marketing of biosimilars. The joint venture was established in 2009. The discontinuation will enable both companies to better advance their own strategies and efforts in serving those healthcare communities. Both companies will continue to explore opportunities to maximize the value of the investments and progress for affordable, efficacious and safe biosimilar treatments.

“With the discontinuation of the joint venture we will cease investing in areas that are not strategic to Lonza such as clinical developments and end product commercialization. In our assessment those investments in biosimilar will require more capital than initially planned and will also take more time until they reach the market. This is why we intend in the future to limit our role by focusing on our core expertise in the areas of contract manufacturing and cell line development,” said Dr Stephan Kutzer, COO, Pharma & Biotech Market Segment, Lonza.

© Worldofchemicals News